Global Alternative Splicing Defects in Human Breast Cancer Cells

被引:6
|
作者
Oh, Jagyeong [1 ]
Pradella, Davide [2 ]
Kim, Yoonseong [1 ]
Shao, Changwei [3 ]
Li, Hairi [3 ]
Choi, Namjeong [1 ]
Ha, Jiyeon [1 ]
Di Matteo, Anna [2 ]
Fu, Xiang-Dong [3 ]
Zheng, Xuexiu [1 ]
Ghigna, Claudia [2 ]
Shen, Haihong [1 ]
机构
[1] Gwangju Inst Sci & Technol, Sch Life Sci, Gwangju 500712, South Korea
[2] CNR, Inst Mol Genet Luigi Luca Cavalli Sforza, Via Abbiategrasso 207, I-27100 Pavia, Italy
[3] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
基金
新加坡国家研究基金会;
关键词
alternative splicing; breast cancer; exon skipping; intrinsically disordered regions; INTRINSICALLY DISORDERED REGIONS; MECHANISMS; MUTATIONS; LINE; CLASSIFICATION; ASSOCIATION; EXPRESSION; THERAPY; REVEALS;
D O I
10.3390/cancers13123071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Aberrant alternative splicing (AS) regulation plays a pivotal role in breast cancer development, progression, and resistance to therapeutical interventions. Indeed, cancer cells can adapt their own transcriptome by changing different AS programs, thus generating cancer-specific AS isoforms involved in every hallmark of cancer. Here, we investigated global AS errors occurring in human breast cancer cells by using RNA-mediated oligonucleotide annealing, selection, and ligation coupled with next-generation sequencing. Our results identified several dysregulated AS events potentially relevant for breast cancer-related biological processes and that provide a better comprehension of the molecular mechanisms that orchestrate the malignant transformation. Breast cancer is the most frequently occurred cancer type and the second cause of death in women worldwide. Alternative splicing (AS) is the process that generates more than one mRNA isoform from a single gene, and it plays a major role in expanding the human protein diversity. Aberrant AS contributes to breast cancer metastasis and resistance to chemotherapeutic interventions. Therefore, identifying cancer-specific isoforms is the prerequisite for therapeutic interventions intended to correct aberrantly expressed AS events. Here, we performed RNA-mediated oligonucleotide annealing, selection, and ligation coupled with next-generation sequencing (RASL-seq) in breast cancer cells, to identify global breast cancer-specific AS defects. By RT-PCR validation, we demonstrate the high accuracy of RASL-seq results. In addition, we analyzed identified AS events using the Cancer Genome Atlas (TCGA) database in a large number of non-pathological and breast tumor specimens and validated them in normal and breast cancer samples. Interestingly, aberrantly regulated AS cassette exons in cancer tissues do not encode for known functional domains but instead encode for amino acids constituting regions of intrinsically disordered protein portions characterized by high flexibility and prone to be subjected to post-translational modifications. Collectively, our results reveal novel AS errors occurring in human breast cancer, potentially affecting breast cancer-related biological processes.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Widespread Alternative Splicing Changes in Metastatic Breast Cancer Cells
    Oh, Jagyeong
    Pradella, Davide
    Shao, Changwei
    Li, Hairi
    Choi, Namjeong
    Ha, Jiyeon
    Ruggiero, Sonia
    Fu, Xiang-Dong
    Zheng, Xuexiu
    Ghigna, Claudia
    Shen, Haihong
    CELLS, 2021, 10 (04)
  • [2] Alternative splicing of transposable elements in human breast cancer
    Nesta, Alex
    Veiga, Diogo F. T.
    Banchereau, Jacques
    Anczukow, Olga
    Beck, Christine R.
    MOBILE DNA, 2025, 16 (01):
  • [3] Aberrant alternative splicing in breast cancer
    Yang, Quan
    Zhao, Jinyao
    Zhang, Wenjing
    Chen, Dan
    Wang, Yang
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (10) : 920 - 929
  • [4] Mutual editing of alternative splicing between breast cancer cells and macrophages
    Ding, Wanbao
    Li, Dongdong
    Zhang, Peixian
    Shi, Lan
    Dai, Hui
    Li, Yan
    Bao, Xin
    Wang, Yue
    Zhang, Honglei
    Deng, Lei
    ONCOLOGY REPORTS, 2019, 42 (02) : 629 - 656
  • [5] Alternative splicing in breast cancer
    Wen Xin
    Yan Ze
    Sha Li
    生物组学研究杂志(英文), 2023, 06 (04)
  • [6] Significance of alternative splicing in cancer cells
    Qi, Fei
    Li, Yong
    Yang, Xue
    Wu, Yan-Ping
    Lin, Lian-Jun
    Liu, Xin-Min
    CHINESE MEDICAL JOURNAL, 2020, 133 (02) : 221 - 228
  • [7] Estrogen receptor beta impacts hormone-induced alternative mRNA splicing in breast cancer cells
    Dago, Dougba Noel
    Scafoglio, Claudio
    Rinaldi, Antonio
    Memoli, Domenico
    Giurato, Giorgio
    Nassa, Giovanni
    Ravo, Maria
    Rizzo, Francesca
    Tarallo, Roberta
    Weisz, Alessandro
    BMC GENOMICS, 2015, 16
  • [8] LncRNA-mediated orchestrations of alternative splicing in the landscape of breast cancer
    Kansara, Samarth
    Sawant, Prajwali
    Kaur, Taranjeet
    Garg, Manoj
    Pandey, Amit Kumar
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2024, 1867 (02):
  • [9] Triple-negative breast cancer cells respond to T cells severely at the alternative splicing layer
    Zhao, Lina
    Yang, Xi
    Feng, Chun
    Wang, Yue
    Wang, Qing
    Pei, Jiahong
    Wu, Jinting
    Li, Shuaiying
    Zhang, Honglei
    Cao, Xianbao
    ELECTRONIC JOURNAL OF BIOTECHNOLOGY, 2021, 50 : 59 - 67
  • [10] The Estrogen Receptor α Signaling Pathway Controls Alternative Splicing in the Absence of Ligands in Breast Cancer Cells
    Elhasnaoui, Jamal
    Ferrero, Giulio
    Miano, Valentina
    Cutrupi, Santina
    De Bortoli, Michele
    CANCERS, 2021, 13 (24)